Preventing Chronic Migraines Has Been Added to the List of Uses for Atogepant.

Published Date: 20 Apr 2023

Qulipta, a medication sold by AbbVie that blocks the calcitonin gene-related peptide receptor, has recently received approval for treating both episodic and chronic migraine. Data from the PROGRESS trial were used to support the FDA's ruling.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot